NXGL

NexGel is a genuine top-line growth story trading at a distressed valuation. Revenue has compounded from $2.05M (FY2022) to $11.4M (FY2025), up 31.5% in the latest year, and the mix is improving: gross profit rose 64.1% and gross margin reached 39.5%, so the consumer-brand roll-up (MedaGel, Kenkoderm, Silly George) plus contract-manufacturing rollstock is scaling with real operating leverage. Losses are narrowing — net income improved to -$3.00M (+8.6% YoY), operating cash burn shrank 66.1% to -$1.31M — and at a $4.79M market cap the stock trades at just 0.4x sales. On trajectory and price alone, this is not a company to short.

But the quality bar is low and the balance sheet is thin. The company has never earned a profit; the accumulated deficit widened to -$21.0M, stockholders' equity fell 22.5% to $4.46M, and ROE is -67.3%. Share count grew 10.7%, so the growth is being funded partly by dilution — a real drag for an 8.48M-share nano-cap. Critically, the provided data gives no current cash figure (the only cash line shown, $13.3M, is stale FY2021 XBRL), so against a continuing operating burn the liquidity runway is unverifiable from this data — a material gap for a cash-consuming micro-cap.